The role of nonselective beta-blockers and somatostatin in The treatment of varicose vein bleeding in cirrhosis of the liver

Cirrhosis of the liver is often accompanied by portal hypertension, which causes dangerous varicose veins of the esophagus and stomach. Untimely stop of bleeding leads to high mortality. Nonselective betablockers and somatostatin are actively used in therapy.

The purpose of the study. Тo analyze the combined treatment of nonselective beta-receptor blockers and somatostatin in the treatment of bleeding from varicose veins of the esophagus and stomach in cirrhosis of the liver.

Мaterials and Methods: A literature review conducted over the past 25 years in Google Scholar, PubMed, and other databases revealed 20 relevant sources. The selected sources meet the inclusion criteria.

Results: NSB, like propranolol, reduces portal pressure, heart rate, and cardiac output. Somatostatin reduces visceral blood flow and inhibits vasodilation, helping to stop bleeding. The combined use of these drugs reduces the risk of recurrent bleeding and the development of hepatorenal syndrome more effectively than monotherapy.

Conclusions: The combined use of NSB and somatostatin increases the effectiveness of the treatment of varicose veins in cirrhosis of the liver and reduces the risk of complications

1. Ivashkin, V. T., Maevskaya, M. V., & Pavlov, C. S. (2016). Diagnostika i lechenie nealkogol'noj zhi- rovoj bolezni pecheni: Klinicheskie rekomendacii Rossijskogo nauchnogo obshhestva po zabolevanijam pecheni i Rossijskogo gastrojenterologicheskogo obshhestva. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 26(2), 24-42. DOI: https://doi.org/10.22416/1382-4376-2016-26-2-24-42 (In Russian).

2. Mukomolov, S. L., Trifonova, G., Levakova, I. A., Bolsun, D., & Krivanogova, E. G. (2016). Hepatitis C in the Russian Federation: Challenges and future directions. Hepatic Medicine: Evidence and Research, 8, 51-60. DOI: https://doi.org/10.2147/HMER.S50172.

3. Kleber, G., & Sauerbruch, T. (2018). Concomitant gastric varices: Bleeding risk sign in patients with liver cirrhosis and esophageal varices? Gastroenterology, 155(5), 1648-1649. DOI: https://doi.org/10.1053/j.gastro.2018.05.053.

4. Sarin, S. K., Choudhury, A., Sharma, M. K., et al. (2019). Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): An update. Hepatology International, 13(4), 353-390. DOI: https://doi.org/10.1007/s12072-019-09946-3.

5. Loffroy, R., Estivalet, L., Cherblanc, V., et al. (2013). Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage. World Journal of Gastroenterology, 19(37), 6131-6143. DOI: https://doi.org/10.3748/wjg.v19.i37.6131.

6. Tseng, Y., Li, F., Wang, J., et al. (2018). Spleen and liver stiffness for noninvasive assessment of portal hypertension in cirrhotic patients with large esophageal varices. Journal of Clinical Ultrasound, 46(7), 442-449. DOI: https://doi.org/10.1002/jcu.22635.

7. Lu, Y. Y., Gao, J. H., Zhao, C., Wen, S. L., Tang, C. W., & Wang, Y. F. (2018). Cyclooxygenase-2 upregulates hepatic somatostatin receptor 2 expression. Scientific Reports, 8(1), 1-11. DOI: https://doi.org/10.1038/s41598-018-29349-y.

8. Mandorfer, M., & Reiberger, T. (2017). Beta blockers and cirrhosis, 2016. Digestive and Liver Disease, 49(1), 3-10. DOI: https://doi.org/10.1016/j.dld.2016.09.013.

9. Rodrigues, S. G., Mendoza, Y. P., & Bosch, J. (2020). Beta-blockers in cirrhosis: Evidencebased indications and limitations. JHEP Reports, 2(1), 100063. DOI: https://doi.org/10.1016/j.jhepr.2019.12.001.

10. Jakab, S. S., & Garcia-Tsao, G. (2020). Evaluation and management of esophageal and gastric varices in patients with cirrhosis. Clinics in Liver Disease, 24(3), 335-350. DOI: https://doi.org/10.1016/j.cld.2020.04.011.

11. Francoz, C., Durand, F., Kahn, J. A., Genyk, Y. S., & Nadim, M. K. (2019). Hepatorenal syndrome. Clinical Journal of the American Society of Nephrology, 14(5), 774-781. DOI: https://doi.org/10.2215/CJN.12451018.

12. Nand, N., Verma, P., & Jain, D. (2019). Comparative evaluation of continuous veno-venous hemodiafiltration and continuous arterio-venous hemodiafiltration in patients of hepatic failure and/or hepatorenal syndrome. The Journal of the Association of Physicians of India, 67(67), 39-42.

13. Tapper, E. B., & Parikh, N. D. (2023). Diagnosis and management of cirrhosis and its complications: A review. JAMA, 329(18), 1589-1602. DOI: https://doi.org/10.1001/jama.2023.5997.

14. Mauro, E., & Gadano, A. (2020). What’s new in portal hypertension? Liver International, 40(Suppl. 1), 122-127. DOI: https://doi.org/10.1111/liv.14366.

15. Pose, E., Piano, S., Juanola, A., & Ginès, P. (2024). Hepatorenal syndrome in cirrhosis. Gastroenterology, 166(4), 588-604. https://doi.org/10.1053/j.gastro.2023.11.306.

16. Gupta, K., Bhurwal, A., Law, C., Ventre, S., Minacapelli, C. D., Kabaria, S., Li, Y., Tait, C., Catalano, C., & Rustgi, V. K. (2021). Acute kidney injury and hepatorenal syndrome in cirrhosis. World Journal of Gastroenterology, 27(26), 3984-4003. DOI: https://doi.org/10.3748/wjg.v27.i26.3984.

17. He, X., Dai, Z., Shi, P., & Hong, J. (2021). Intravenous drip of somatostatin followed by restricted fluid resuscitation to treat upper gastrointestinal bleeding in patients with liver cirrhosis. Evidence-Based Complementary and Alternative Medicine, 2021, 6548479. DOI: https://doi.org/10.1155/2021/6548479.

18. Liu, X., Guo, X., & Zhou, H. (2021). Octreotide acetate combined with somatostatin upregulates miR-1291 and downregulates miR-331-3p in patients with cirrhosis and upper gastrointestinal bleeding. American Journal of Translational Research, 13(8), 9883-9891.

19. Albillos, A., & Krag, A. (2023). Beta-blockers in the era of precision medicine in patients with cirrhosis. Journal of Hepatology, 78(4), 866-872. DOI: https://doi.org/10.1016/j.jhep.2022.12.005.

20. Møller, S., Danielsen, K. V., Nabilou, P., Kimer, N., & Bendtsen, F. (2023). Beta-adrenergic blockade in cirrhosis – Harmful or helpful? Expert Review of Gastroenterology & Hepatology, 17(6), 519-529. DOI: https://doi.org/10.1080/17474124.2023.2215428.

21. Burza, M. A., Marschall, H. U., Napoleone, L., & Molinaro, A. (2017). The 35-year odyssey of beta blockers in cirrhosis: Any gender difference in sight? Pharmacological Research, 119, 20-26. DOI: https://doi.org/10.1016/j.phrs.2017.01.015.

22. Mao, G., Li, C., Wang, H., Jv, Y. H., Zhang, Y., & Liu, L. (2022). Exploration on the effect of nonselective β-receptor blockers (NSBBs) on hemodynamic parameters in complicated liver cirrhosis. BioMed Research International, 2022, 7922906. DOI: https://doi.org/10.1155/2022/7922906.

23. Garbuzenko, D. V. (2024). Contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis patients. World Journal of Hepatology, 16(2), 126- 134. DOI: https://doi.org/10.4254/wjh.v16.i2.126.

24. Gracia-Sancho, J., Maeso-Díaz, R., & Bosch, J. (2015). Pathophysiology and a rational basis of therapy. Digestive Diseases, 33(4), 508-514. DOI: https://doi.org/10.1159/000374099. 25. Nair, H., Berzigotti, A., & Bosch, J. (2016). Emerging therapies for portal hypertension in cirrhosis. Expert Opinion on Emerging Drugs, 21(2), 167-181. h DOI: ttps://doi.org/10.1080/14728214.2016.1184647.

25. Gracia-Sancho, J., Maeso-Díaz, R., Fernández-Iglesias, A., Navarro-Zornoza, M., & Bosch, J. (2015). New cellular and molecular targets for the treatment of portal hypertension. Hepatology International, 9(2), 183-191. DOI: https://doi.org/10.1007/s12072-015-9613-5.

26. Snyder, P., Ali, R., Poles, M., & Gross, S. A. (2015). Portal hypertensive gastropathy with a focus on management. Expert Review of Gastroenterology & Hepatology, 9(9), 1207-1216. DOI: https://doi.org/10.1586/17474124.2015.1059275.